The Peptide Reference
The Peptide Reference
References
Reference/Tetrapeptide bioregulator

Livagen

KEDA Tetrapeptide · Liver Bioregulator

research use only

Livagen is a Khavinson bioregulator tetrapeptide (KEDA) with significant hepatoprotective and immunomodulatory properties. Structurally similar to Epitalon, it normalizes immune and antioxidant status while restoring liver function in hepatitis conditions. Livagen is best known for its ability to decondense chromatin, activating silent genes including ribosomal genes to boost protein synthesis and cellular activity. Maximum protective effects occur during aging.

Significant hepatoprotective propertiesDecondenses chromatin to activate genesRestores liver function in hepatitisNormalizes immune status
01

Overview

Livagen is a Khavinson bioregulator tetrapeptide (KEDA) with significant hepatoprotective and immunomodulatory properties. Structurally similar to Epitalon, it normalizes immune and antioxidant status while restoring liver function in hepatitis conditions. Livagen is best known for its ability to decondense chromatin, activating silent genes including ribosomal genes to boost protein synthesis and cellular activity. Maximum protective effects occur during aging.

Livagen works through direct effects on DNA structure and function. It decondenses chromatin (tightly packed DNA), increasing expression of certain genes and improving the 'youthful' profile of cells. The peptide activates multiple genes in lymphocytes, including previously silent ribosomal genes, boosting protein synthesis and cell activity. It exhibits hepatoprotective effects through normalizing immune and antioxidant status in liver tissue.

02

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Liver Support3
Hepatoprotection

Protects liver tissue through normalizing immune and antioxidant status.

Moderate
Hepatitis Support

Restores liver functions in both acute and chronic hepatitis models.

Moderate
Liver Fibrosis

Shows protective properties in liver fibroid induration models.

Small
Anti-Aging3
Chromatin Remodeling

Decondenses chromatin to restore youthful gene expression patterns.

Moderate
Age-Related Liver Decline

Maximum hepatoprotective effects occur during aging.

Moderate
Gene Activation

Activates silent genes including ribosomal genes for improved protein synthesis.

Small
Immune Support1
Immunomodulation

Normalizes immune function alongside liver protective effects.

Small
i

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only
Class
Tetrapeptide bioregulator
Chain length
4 residues
Molecular weight
432 Da
Typical dose
10-20 mg daily
Frequency
Daily for 10-20 days per cycle
Cycle length
10-20 days
Storage
Oral capsules: Room temperature. Injectable reconstituted: 2-8°C refrigerated
03

Molecular data

Type
Tetrapeptide bioregulator
Molecular weight
432 Da
Chain length
4 residues
Primary sequenceN → C · 4 residues
H₂N–
KLys1
EGlu2
DAsp3
AAla4
–OH
KEDA
NonpolarPolarAcidicBasic
04

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

ContextRouteAmountFrequency
Standard protocolOral capsules10-20 mgDaily for 10-20 days
MaintenanceOral capsules10 mg2-3 cycles yearly
Research protocolIM or SubQ10 mgDaily for 10 days
05

Interactions

Epitalon

Structurally similar; often combined in comprehensive anti-aging protocols.

synergistic
Glutathione

Both support liver function and antioxidant status.

synergistic
Ovagen

Complementary liver bioregulators with different sequences.

synergistic
Vilon

Different organ targets; can be combined in bioregulator protocols.

compatible
06

Quality checklist

  • White powder or capsules
  • Clear solution if reconstituted
  • Proper packaging and labeling
  • !Unknown source or purity
  • ×Discoloration
  • ×Unusual odor
  • ×Damaged packaging
07

What to expect

During cycleChromatin remodeling and gene expression changes begin
Post-cycleEffects persist due to epigenetic changes
Weeks-MonthsLiver function improvements
Long-termCumulative benefits with periodic cycles
08

Safety

Commonly reported2
  • Generally well-tolerated
  • Minimal side effects reported
Stop and seek advice2
  • Allergic reactions
  • Unusual liver symptoms
Contraindications3
  • Active liver emergencies (seek medical care)
  • Known hypersensitivity
  • Pregnancy or breastfeeding
09

FAQ

What does 'decondensing chromatin' actually do?

Chromatin decondensation refers to loosening tightly-packed DNA, making previously silent genes accessible for expression. Livagen activates this process, turning on genes related to protein synthesis and cellular function that typically decrease with age. This restores more youthful gene expression patterns.

Is Livagen the same as Epitalon?

No, though they're both Khavinson bioregulator tetrapeptides with similar structures. Livagen (KEDA) focuses on liver function and chromatin remodeling, while epitalon targets the pineal gland. They're often used together in comprehensive anti-aging protocols.

How do I know if Livagen is working?

Benefits from Livagen are subtle and build over weeks. Liver function markers (transaminases, bilirubin) may improve on blood work. Systemic effects include improved immune markers and energy. Results are assessed best through lab work and multi-week observation rather than immediate symptoms.

Can I take Livagen continuously or do I need to cycle?

Traditional protocols recommend 10-20 day cycles, 2-3 times per year with breaks between cycles. This allows chromatin changes and gene expression effects to take hold while avoiding potential adaptation. Continuous daily use hasn't been well-studied.

For research use only. Nothing on this page is medical advice, and no number here is a recommendation to dose.